Physician profile
Michael Lawrence
NPI 1477506541
$10,544.16
in general payments reported to CMS, 2019-2025
38 companies · $2,376 in 2025
The $2,376 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $1,159 · 2021: $1,336 · 2022: $1,596 · 2023: $1,475 · 2024: $1,258 · 2025: $2,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,954 · Education: $137 · Consulting Fee: $16.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,954.38 |
| Education | $137.45 |
| Consulting Fee | $16.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,268.00 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genentech USA, INC. | $1,626.53 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $1,430.45 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $1,175.43 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $479.77 | 2019-2025 | Dupixent |
| Pfizer INC. | $465.23 | 2019-2025 | |
| Grifols USA, LLC | $444.45 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.11 | 2019-2023 | Spiriva Respimat |
| Octapharma USA, INC. | $275.21 | 2019-2025 | Cutaquig |
| Pharming Healthcare, INC. | $264.10 | 2021-2025 | Ruconest |
| Amgen INC. | $251.76 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $208.00 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Genzyme Corporation | $177.91 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $144.67 | 2020-2021 | |
| Leo Pharma INC. | $133.87 | 2023 | Adbry |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $130.69 | 2020-2024 | Auvi-Q |
| Optinose US, INC. | $115.21 | 2020-2025 | |
| Abbvie INC. | $108.24 | 2022-2024 | |
| Ars Pharmaceuticals Operations, INC. | $72.93 | 2025 | Neffy |
| Gc Biopharma USA, INC. | $52.91 | 2025 | Alyglo |
| Covis Pharma Gmbh | $33.14 | 2021 | |
| Circassia INC. | $32.48 | 2019 | |
| Galderma Laboratories, L.P. | $31.39 | 2025 | Nemluvio |
| Shire North American Group INC | $29.33 | 2019 | |
| Mylan Specialty L.P. | $28.62 | 2021 | |
| Csl Behring | $28.26 | 2019 | |
| Organon LLC | $27.36 | 2025 | Vtama |
| Greer Laboratories, INC. | $26.66 | 2019 | |
| Lilly USA, LLC | $24.58 | 2025 | Ebglyss |
| Cycle Pharmaceuticals INC | $24.51 | 2025 | Sajazir |
| Aimmune Therapeutics, INC. | $20.17 | 2022 | |
| Merck Sharp & Dohme LLC | $19.28 | 2021 | |
| Adma Biomanufacturing LLC | $16.44 | 2025 | |
| Hikma Pharmaceuticals USA | $16.26 | 2023 | Kloxxado |
| Alk-Abello, INC | $16.08 | 2019 | |
| Verona Pharma, INC. | $15.29 | 2025 | Ohtuvayre |
| Mylan Pharmaceuticals INC. | $15.21 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.